# An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

> **NCT07188844** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Immunovant Sciences GmbH** · enrollment: 108 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Batoclimab

## Key facts

- **NCT ID:** NCT07188844
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-08-28
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188844, "An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07188844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*